NewswireToday - /newswire/ -
Minneapolis, MN, United States, 2007/02/08 - ATS Medical, Inc. (Nasdaq: ATSI) today announced that it has been selected to receive the 2006 North American Frost & Sullivan Award for Growth Strategy Leadership in the U.S. artificial heart valves market.
The award is presented each year to a company that has demonstrated an exceptional growth strategy.
Venkat Rajan, Research Analyst for Frost & Sullivan noted, "We are very pleased to recognize ATS Medical for their innovative and forward thinking strategies that have turned them into one of the few heart valve therapy manufacturers witnessing high growth rates. In the past year, they have expanded their product portfolio to include bioprosthetic and valve repair products in addition to their already successful ATS Open Pivot® Mechanical Heart Valves. The completed acquisition of 3f Therapeutics has been the most significant recent acquisition activity within the heart valve industry and provides the company with a foothold in the expanding bioprosthetic valve market segment through its ATS 3F® brand of tissue valve products. Their ability to grow revenues by 24 percent in a mature market while implementing a diversification strategy that will have lasting impact on that market has shown ATS Medical to be a worthy recipient of this year's award."
Michael Dale, ATS Medical President and CEO said, "Frost & Sullivan employs comprehensive research, tracking and stringent objective assessment criteria in identifying candidates for their Growth Strategy Leadership awards. It is gratifying to be recognized for bolstering our presence in the heart valve therapy market place and positioning ATS Medical for continued growth."
About ATS Medical
ATS Medical, Inc. provides innovative products and services focused on cardiac surgery. The company, global in scope, has been headquartered in Minneapolis, Minnesota since its founding in 1991. More than 130,000 ATS Open Pivot® Heart Valves, which utilize a unique pivot design resulting in exceptional performance and low risk profile, have been implanted in patients worldwide. The ATS 3F brand encompasses multiple tissue heart valve product offerings at varying steps from market introductions to clinical trials to development projects that incorporate less invasive valve replacement technology. ATS Medical's focus on cardiac surgery is further strengthened by offerings that include ATS Simulus™ annuloplasty products for heart valve repair, SurgiFrost® and FrostByte™ products for surgical cryoablation of cardiac arrhythmias, RTI-Cardiovascular for allograft tissue services, and the development of PARSUS blood filtration technology.
This Press Release contains forward-looking statements that may include statements regarding intent, belief or current expectations of the Company and its management. For a discussion of these and other risks and
uncertainties that could affect the Company's activities and results, please refer to the Company's filings with the Securities and Exchange Commission including its Form 10-K for the year ended December 31, 2005, as amended, and its Form S-4 Registration Statement, as amended, filed with respect to the merger with 3F Therapeutics.